Fig. 1: Co-Mutation Patterns & adverse cytogenetic findings observed in the TP53 Cohort. | Blood Cancer Journal

Fig. 1: Co-Mutation Patterns & adverse cytogenetic findings observed in the TP53 Cohort.

From: Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Fig. 1

This figure illustrates the patterns of co-mutations identified in the TP53 cohort, categorized by treatment arm. Additionally, the data was further stratified based on two groups: the patients who achieved CR/CRi (A) and the primary refractory group (B).

Back to article page